ST PHARM CO., LTD. Logo

ST PHARM CO., LTD.

A global CDMO specializing in APIs for gene therapies and small molecule drugs.

237690 | KO

Overview

Corporate Details

ISIN(s):
KR7237690003
LEI:
Country:
South Korea
Address:
경기도 시흥시 협력로 231(정왕동, 시화공단 1나 802호), 시흥시

Description

ST PHARM CO., LTD. is a global Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs). The company provides technology-driven manufacturing services for gene therapies, with core expertise in oligonucleotides and various forms of RNA (xRNA), including messenger RNA (mRNA). In addition to nucleic acid-based medicines, ST Pharm offers custom manufacturing for small molecule APIs. The company's services operate under cGMP (current Good Manufacturing Practice) standards, providing comprehensive solutions that support the entire drug development lifecycle, from research and development to commercial-scale production for its global pharmaceutical partners.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-09-10 00:00
기업설명회(IR)개최
Korean 8.3 KB
2025-09-08 00:00
전환청구권행사
Korean 10.8 KB
2025-08-14 00:00
[기재정정]사업보고서 (2024.12)
Korean 3.4 MB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 2.6 MB
2025-08-13 00:00
기업설명회(IR)개최
Korean 7.0 KB
2025-07-25 00:00
주식등의대량보유상황보고서(일반)
Korean 119.1 KB
2025-07-24 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.8 KB
2025-07-24 00:00
기업설명회(IR)개최
Korean 7.0 KB
2025-07-18 00:00
결산실적공시예고
Korean 3.8 KB
2025-07-18 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-06-23 00:00
지속가능경영보고서등관련사항(자율공시)
Korean 11.9 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.6 MB
2025-05-08 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 26.3 KB
2025-05-08 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 32.2 KB

Automate Your Workflow. Get a real-time feed of all ST PHARM CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ST PHARM CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ST PHARM CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.